Noratis AG (HAM:NUVA) Net Change in Cash : €-0.07 Mil (TTM As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Noratis AG Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Noratis AG's Net Change in Cash for the six months ended in Jun. 2023 was €-0.04 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.07 Mil.

Noratis AG Net Change in Cash Historical Data

The historical data trend for Noratis AG's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noratis AG Net Change in Cash Chart

Noratis AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Change in Cash

Get a 7-Day Free Trial

-10.04

-0.88

24.07

-22.31

2.44

Noratis AG Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Net Change in Cash	Get a 7-Day Free Trial											-23.05	0.74	2.46	-0.02	-0.04

Noratis AG Net Change in Cash Calculation

Noratis AG's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-33.029	+	0.052	+	35.412	+	0
	=	2.44

Noratis AG's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 12.614 + 1.689 + -14.345 + 0

= -0.04

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noratis AG Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Noratis AG's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Noratis AG (HAM:NUVA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Noratis AG (HAM:NUVA) » Definitions » Net Change in Cash

Comparable Companies

LSE:DRX LSE:ETP LSE:GOOD LSE:SAE LSE:OPG LSE:CODX HKSE:00016 HKSE:01109 HKSE:00688 HKSE:01113 TSE:1925 SHSE:600048 SZSE:000002 BOM:532868 DFM:EMAAR SZSE:001979 ADX:ALDAR HKSE:00960 PHS:HVN BOM:543287

Traded in Other Exchanges

NUVA:Germany

Address

Hauptstrasse 129, Eschborn, HE, DEU, 65760

Website

https://www.noratis.de

Noratis AG is a developer of residential property portfolios. The company invests in residential properties with technical and commercial development potential in Germany, mainly in small and medium-sized towns or on the outskirts of metropolitan areas. The Company specializes in the upgrading of ageing residential portfolios, mostly company-owned apartments, residential areas or housing estates in cities with more than 10,000 inhabitants and in peripheral areas of conurbations.

Noratis AG (HAM:NUVA) Headlines

From GuruFocus

ALERT: The M&A Class Action Firm Continues its Investigation of the Merger � ANGN, CSII, AGFS, NUVA
By sperokesalga sperokesalga • 03-29-2023

NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results
By PRNewswire • 07-24-2023

Globus Medical and NuVasive to Combine in All-Stock Transaction to Create Innovative Global Musculoskeletal Company Focused on Patient Care
By PRNewswire PRNewswire • 02-09-2023

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending NuVasive Shareholders Vote "FOR" the Proposed Merger with Globus Medical
By PRNewswire PRNewswire • 04-17-2023

NUVA Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Merger of NuVasive With Globus Medical
By sperokesalga sperokesalga • 02-09-2023

NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting
By PRNewswire • 08-30-2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NUVA, SUMO
By sperokesalga sperokesalga • 02-12-2023

NuVasive Enhances C360 Portfolio with Expanded Indications for Modulus Cervical and Attrax Putty
By PRNewswire PRNewswire • 02-21-2023

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq � NUVA), Oak Street Health (NYSE � OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq � CSII)
By sperokesalga sperokesalga • 02-22-2023

NuVasive to Participate in Piper Sandler 34th Annual Healthcare Conference
By PRNewswire PRNewswire • 11-16-2022